Results 1 to 10 of about 206,382 (334)

The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. [PDF]

Thromb Haemost, 2023
Background  Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due to interactions or reduced adherence, but comparative data are lacking ...
Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L.   +4 more
europepmc   +2 more sources

Current Clinician Perspective on Non-vitamin K antagonist Oral Anticoagulant Use in Challenging Clinical Cases [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Uğur Önsel Türk
openalex   +3 more sources

The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation [PDF]

, 2015
Funding The National Institute for Health Research Health Technology Assessment programme.Peer reviewedPublisher ...
Pawana Sharma, Graham Scotland, Moira Cruickshank, Emma Tassie, Cynthia Fraser, Christopher Burton, Bernard Croal, Craig Ramsay, Miriam Brazzelli   +8 more
openalex   +4 more sources

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study [PDF]

British medical journal, 2016
Objective To study the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant naïve patients with atrial fibrillation ...
Torben Bjerregaard Larsen, Flemming Skjøth, Peter Brønnum Nielsen, Jette Nordstrøm Kjældgaard, Gregory Y.H. Lip   +4 more
openalex   +2 more sources

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia. [PDF]

Biology (Basel), 2023
Malagù M, Longo F, Marchini F, Sirugo P, Capanni A, Clò S, Mari E, Culcasi M, Bertini M.   +8 more
europepmc   +2 more sources

Can Differences in Non-Vitamin K Antagonist Oral Anticoagulant Preferences Result in Varying Clinical Outcomes in Patients with Atrial Fibrillation? [PDF]

Anatol J Cardiol, 2023
Özlek B.
europepmc   +2 more sources

Determining Drug Exposure Based on Medication Dispensing Data: A Validation Study of Vitamin K Antagonist Treatment Episodes Against INR Records. [PDF]

Pharmacoepidemiol Drug Saf
Kempers EK, Visser C, Goedegebuur J, Chen Q, Søgaard M, Ording AG, van den Dries C, Abbel D, Aldridge SJ, Lifford KJ, Portielje JEA, Nierman MC, Boetes-Draisma A, van de Leur SJCM, Klok FA, Geijteman ECT, Kruip MJHA, Cannegieter SC.   +17 more
europepmc   +3 more sources

A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study

Circulation, 2022
Background: Non–vitamin K oral anticoagulants have become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF).
H. Reinecke, C. Engelbertz, R. Bauersachs, G. Breithardt, Hans-Herbert Echterhoff, J. Gerss, K. Haeusler, B. Hewing, J. Hoyer, Sabine Juergensmeyer, T. Klingenheben, G. Knapp, Lars Christian Rump, H. Schmidt-Guertler, C. Wanner, P. Kirchhof, D. Goerlich   +16 more
semanticscholar   +1 more source

Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

Circulation, 2023
BACKGROUND: There is ambiguity whether frail patients with atrial fibrillation managed with vitamin K antagonists (VKAs) should be switched to a non–vitamin K oral anticoagulant (NOAC).
L. P. Joosten, S. van Doorn, P. M. van de Ven, Bart T G Köhlen, M. Nierman, H. Koek, M. Hemels, M. Huisman, M. Kruip, Laura M. Faber, N. M. Wiersma, W. F. Buding, Rob Fijnheer, H. Adriaansen, Kit Roes, A. Hoes, Frans H. Rutten, G. Geersing   +17 more
semanticscholar   +1 more source

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.

New England Journal of Medicine, 2021
BACKGROUND The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied.
N. V. Van Mieghem, M. Unverdorben, C. Hengstenberg, H. Möllmann, R. Mehran, D. Lopez-Otero, L. Nombela‐Franco, R. Moreno, P. Nordbeck, H. Thiele, I. Lang, J. Zamorano, F. Shawl, M. Yamamoto, Y. Watanabe, K. Hayashida, R. Hambrecht, F. Meincke, P. Vranckx, James Jin, E. Boersma, J. Rodés‐Cabau, P. Ohlmann, P. Capranzano, Hyo‐Soo Kim, T. Pilgrim, Richard Anderson, U. Baber, A. Duggal, P. Laeis, H. Lanz, Cathy Chen, M. Valgimigli, R. Veltkamp, S. Saito, G. Dangas   +35 more
semanticscholar   +1 more source